AstraZeneca PLC
www.astrazeneca.com
Latest From AstraZeneca PLC
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.
Amicus Makes Its Gene Therapy Move, Focusing On CNS Lysosomal Storage Disorders
The rare disease specialist gained 10 gene therapy programs with the acquisition of Celenex, including two in clinical-stage development for Batten disease, in exchange for $100m up front. President Bradley Campbell talked to Scrip about the process that led to the deal and next steps for development.
Phase III Roxadustat ALPS Data Positive For New Class Of Anemia Therapies
Positive top-line data from the ALPS study confirms the efficacy and safety of roxadustat, a Phase III-stage product which could be the first a new class of orally active agents with potential in the treatment of anemia associated with chronic kidney disease.
Assessing Artios: $83m Series B, Big-Name Investors, Nothing In The Clinic
Cambridge, UK-based Artios Pharma attracted several new investors for its over-subscribed series B round in August 2018, but the company is yet to enter the clinic with its DNA repair drug portfolio and has many hurdles ahead to validate its technology. Scrip speaks to investors from LSP and Arix about why preclinical-stage biotechs are getting more attention in 2018.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Cardiovascular
- Gastrointestinal
- Infectious & Viral Diseases
- Inflammation
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
UK
-
UK
-
Western Europe
-
Europe
- Company Type
- Big Pharma
- Parent & Subsidiaries
-
AstraZeneca PLC
- Acerta Pharma BV
- Ardea Biosciences Inc.
- Arrow Therapeutics Ltd.
- Astra Arcus
- Astra Draco AB
- Astra GMBH
- Astra Hassle AB
- Astra Japan Ltd.
- AstraZeneca AB
- AstraZeneca KK
- AstraZeneca LP
- AstraZeneca Pharma India Ltd.
- AstraZeneca Pharmaceuticals LP
- AstraZeneca UK Ltd.
- Australian Monoclonal Antibody Development Pty Ltd
- Cambridge Research Biochemicals Inc.
- Cambridge Research Biochemicals Ltd.
- ICI Americas Inc.
- ICI Australia
- KuDOS Pharmaceuticals Ltd.
- Laboratorio Ifesa SA
- MedImmune Inc.
- MedImmune LLC
- Novexel SA
- Omthera Pharmaceuticals Inc.
- Pearl Therapeutics Inc.
- Salick Health Care Inc.
- Simes SRL
- Stuart Disease Management Services
- Stuart Pharmaceuticals Inc.
- Symbicom AB
- Zeneca Agrochemicals
- Zeneca Group PLC
- Zeneca Inc.
- Zeneca Pharma Inc.
- Zeneca Pharmaceuticals
- ZS Pharma Inc.
- Senior Management
-
Pascal Soriot, CEO
Marc Dunoyer, CFO
Sean Bohen, MD, PhD, EVP, Global Medicines Dev. & CMO - Contact Info
-
AstraZeneca PLC
Phone: (44) 20 7604 8000
2 Kingdom St.
London, W2 6BD
UK
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice